Trial Profile

Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Paclitaxel
Indications HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ETNA

Most Recent Events

30 Jan 2025 Planned End Date changed from 1 Dec 2031 to 1 Jan 2032.
30 Jan 2025 Planned primary completion date changed from 1 Dec 2031 to 1 Jan 2032.
13 Dec 2024 Study design were presented at the 47th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com